Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 13/20 | 0.46 |
| ▸ | LCK | P06239 | 6/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6489043 | 0.99 | PTGES (0.46) | PTGESLCKEGFRSRCZAP70 | |
| SCHEMBL5695236 | 0.84 | LCK (0.51) | PTGESLCKEGFRSRCZAP70 | |
| Hydrochloric Acid SCHEMBL6497662 | 0.83 | LCK (0.50) | PTGESLCKEGFRSRCZAP70 | |
| SCHEMBL5695281 | 0.79 | JAK2 (0.46) | PTGESLCKEGFRSRCZAP70 | |
| SCHEMBL5695257 | 0.79 | LCK (0.54) | PTGESLCKEGFRSRCZAP70 | |
| Hydrochloric Acid SCHEMBL6492502 | 0.78 | LCK (0.53) | PTGESLCKEGFRSRCZAP70 | |
| Hydrochloric Acid SCHEMBL6491671 | 0.78 | JAK2 (0.46) | PTGESLCKEGFRSRCZAP70 | |
| SCHEMBL5695250 | 0.78 | ADRA2A (0.41) | PTGESLCKEGFRSRCZAP70 | |
| SCHEMBL5695251 | 0.77 | HDAC11 (0.52) | PTGESLCKEGFRSRCZAP70 | |
| Hydrochloric Acid SCHEMBL6489052 | 0.77 | ADRA2A (0.40) | PTGESLCKEGFRSRCZAP70 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1341770-B1 | SUBSTITUTED 2-ANILINO-BENZIMIDAZOLES AND THE USE THEREOF AS NHE-INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-06-14 | — | — | EP | claimed |
| US-6686384-B2 | 2-ANILINOPHENYL-SUBSTITUTED; INHIBITION OF THE NA+/H+ EXCHANGER | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-03 | — | — | US | claimed |
| US-20030191170-A1 | Substituted benzimidazoles, processes for their preparation, their use as medicaments, and medicaments comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-10-09 | — | — | US | claimed |
| EP-1341770-A1 | SUBSTITUTED 2-ANILINO-BENZIMIDAZOLES AND THE USE THEREOF AS NHE-INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2003-09-10 | — | — | EP | claimed |
| US-20020132842-A1 | Substituted benzimidazoles, processes for their preparation, their use as medicaments, and medicaments comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-09-19 | — | — | US | claimed |
| WO-2002046169-A1 | SUBSTITUTED 2-ANILINO-BENZIMIDAZOLES AND THE USE THEREOF AS NHE-INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-06-13 | — | — | WO | claimed |
| EP-1341770-B1 | SUBSTITUTED 2-ANILINO-BENZIMIDAZOLES AND THE USE THEREOF AS NHE-INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-06-14 | — | — | EP | disclosed |
| US-6958357-B2 | Substituted benzimidazoles, processes for their preparation, their use as medicaments, and medicaments comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-10-25 | — | — | US | disclosed |
| US-6686384-B2 | 2-ANILINOPHENYL-SUBSTITUTED; INHIBITION OF THE NA+/H+ EXCHANGER | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-03 | — | — | US | disclosed |
| US-20030191170-A1 | Substituted benzimidazoles, processes for their preparation, their use as medicaments, and medicaments comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-10-09 | — | — | US | disclosed |
| EP-1341770-A1 | SUBSTITUTED 2-ANILINO-BENZIMIDAZOLES AND THE USE THEREOF AS NHE-INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2003-09-10 | — | — | EP | disclosed |
| US-20020132842-A1 | Substituted benzimidazoles, processes for their preparation, their use as medicaments, and medicaments comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-09-19 | — | — | US | disclosed |
| WO-2002046169-A1 | SUBSTITUTED 2-ANILINO-BENZIMIDAZOLES AND THE USE THEREOF AS NHE-INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191170-A1 | Substituted benzimidazoles, processes for their preparation, their use as medicaments, and medicaments comprising them | ABCB11, ATP1A2, ATP1A1 | PTGES 2271/4885LCK 4175/4885EGFR 3615/4885 |
| US-20020132842-A1 | Substituted benzimidazoles, processes for their preparation, their use as medicaments, and medicaments comprising them | ABCB11, ATP1A2, ATP1A1 | PTGES 2271/4885LCK 4175/4885EGFR 3615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.